文献速递乳腺癌支持与姑息治疗

针刺预防紫杉醇所致周围神经病变加重的IIA期试验

A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
PubMed 文献 · Eur J Cancer · 2018-07-13

该IIA期单臂试验在每周紫杉醇辅助/新辅助治疗的I-III期乳腺癌患者中评估针刺预防CIPN加重的初步疗效。104例筛查中37例(36%)出现II级CIPN,28例入组干预,27例可评估者中26例未进展为III级CIPN,达到预设成功标准;FACT/GOG-Ntx与NPS评分稳定,针刺耐受良好。

要点

  • 27例接受针刺者中26例完成紫杉醇治疗且未出现III级CIPN,达到预设成功标准。
  • 干预期间FACT/GOG-Ntx与NPS评分保持稳定。
  • 针刺耐受良好,27例中4例(15%)报告I级瘀斑。

核心结论

  • 针刺在每周紫杉醇化疗期间预防高级别CIPN方面安全并显示初步有效性。
  • 需后续随机对照试验确立其在CIPN预防中的确切疗效。

研究设计与样本

  • IIA期单臂临床试验,筛查接受新辅助/辅助每周紫杉醇的I-III期乳腺癌患者。
  • 104例筛查中37例(36%)出现II级CIPN,28例(27%)入组干预,1例因方案违背剔除,27例可评估。
  • 主要目标为评估针刺预防NCI-CTCAE 4.0版II级CIPN向更高级别进展的疗效。
  • 预设成功标准为27例入组患者中≥23例未出现III级CIPN。

主要发现

  • 27例接受针刺者中26例完成紫杉醇治疗且未出现III级CIPN,达到预设成功标准。
  • 干预期间FACT/GOG-Ntx与NPS评分保持稳定。
  • 针刺耐受良好,27例中4例(15%)报告I级瘀斑。

关键数值与推荐

  • 主要终点采用NCI-CTCAE 4.0版CIPN分级。
  • 预设成功标准为27例中≥23例未进展为III级CIPN。
  • 结局指标包括NCI-CTCAE CIPN分级、FACT/GOG-Ntx与NPS,干预期间每周评估。

临床怎么用

  • 对每周紫杉醇治疗中出现II级CIPN的乳腺癌患者,可考虑针刺以预防进展为III级CIPN。
  • 针刺耐受性良好,常见I级瘀斑。
  • 当前证据为单臂初步结果,尚不能替代随机对照证据。

局限性

  • 单臂设计,无对照组,无法排除自然病程或其他因素影响。
  • 样本量小,仅27例可评估。
  • 仅为IIA期初步疗效评估,需随机对照试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting side-effect of neurotoxic chemotherapy for cancer patients. We evaluated the preliminary efficacy of acupuncture in preventing worsening CIPN in patients receiving paclitaxel. METHODS: In this phase IIA single-arm clinical trial, we screened stage I-III breast cancer patients receiving neoadjuvant/adjuvant weekly paclitaxel for development of CIPN. The primary objective was to assess acupuncture's efficacy in preventing the escalation of National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.0, grade II CIPN to higher grades. Acupuncture was deemed worthy of further study if 23 or more of the 27 enrolled patients did not develop grade III CIPN. Outcome measures (NCI-CTCAE CIPN grade, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-Ntx], Neuropathic Pain Scale [NPS]) were obtained weekly during the intervention. RESULTS: Of 104 patients screened, 37 developed grade II CIPN (36%), and 28 (27%) enrolled into the intervention phase; one was removed due to protocol violation. Of the 27 patients receiving acupuncture, 26 completed paclitaxel treatment without developing grade III CIPN, meeting our prespecified success criteria for declaring acupuncture worthy of further study. FACT/GOG-Ntx and NPS scores remained stable during the intervention while continuing weekly paclitaxel. Acupuncture treatment was well tolerated; 4 of 27 (15%) patients reported grade I bruising. CONCLUSIONS: Acupuncture was safe and showed preliminary evidence of effectiveness in reducing the incidence of high grade CIPN during chemotherapy. A follow-up randomised controlled trial is needed to establish definitive efficacy in CIPN prevention for patients at risk.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bao T, Seidman AD, Piulson L, et al. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. Eur J Cancer. 2018. PMID: 30007894. doi:10.1016/j.ejca.2018.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。